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Abstract 18	
Prader-Willi Syndrome (PWS) is a complex genetic disorder characterized by developmental and 19	
growth abnormalities, insatiable appetite, and excessive eating (hyperphagia). The underlying cause 20	
of hyperphagia in PWS is currently unknown, however, elevated levels of the peptide hormone 21	
ghrelin is believed to contribute. Recently, ghrelin-reactive autoantibodies (isotype IgG) were 22	
identified in non-genetic obesity. These autoantibodies act as ghrelin carrier proteins and potentiate its 23	
orexigenic effects. Here, we describe the identification of ghrelin-reactive autoantibodies in a cohort 24	
of 16 children with PWS. In comparison to unaffected siblings, autoantibody levels are significantly 25	
increased in PWS children. We further show that autoantibody levels are unaffected by food intake, 26	
unlike plasma ghrelin which declines postprandially in both groups. Critically, we also demonstrate 27	
that the autoantibodies bind the major circulating ghrelin isoforms, unacylated ghrelin, which does not 28	
stimulate appetite, and the orexigen acylated ghrelin. In excess, unacylated ghrelin may compete with 29	
acylated ghrelin for autoantibody binding. Taken together, this is the first report on ghrelin-reactive 30	
antibodies in a pediatric population, and the first to demonstrate that the antibodies do not 31	
discriminate between orexigenic and non-orexigenic ghrelin isoforms. Our work suggests that ghrelin 32	
autoantibodies can be targeted using non-orexigenic forms of ghrelin, thereby providing a novel 33	
therapeutic target for PWS and for obesity in general. 34	
 35	
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Introduction 37	
Prader-Willi Syndrome (PWS) is the most common genetic cause of obesity in children and is 38	
characterized by developmental and growth abnormalities, insatiable appetite and impaired satiety [1]. 39	
PWS patients also exhibit high levels of the orexigenic peptide hormone ghrelin. The two major forms 40	
of ghrelin in the circulation are acyl ghrelin, which potently stimulates appetite and food-seeking 41	
behaviour, and unacylated ghrelin (UAG), which has no effect on appetite [2-4]. Recently, ghrelin-42	
reactive autoantibodies (isotype IgG) were identified in non-genetic obesity [5]. These autoantibodies 43	
bind ghrelin reversibly, acting as carrier proteins that protect ghrelin from degradation and potentiate 44	
its orexigenic effects [5]. Here, we sought to further explore this association by characterizing ghrelin 45	
autoantibodies in children with PWS and non-affected sibling controls.  46	
 47	
Methods 48	
Sixteen children with PWS and 16 controls, matched for body mass index (BMI), were recruited to 49	
the study. Plasma was collected after an overnight fast (baseline), and 10, 20, 30, 60 and 120 minutes 50	
after a standardized mixed meal. Plasma acylated ghrelin levels were measured by ELISA (Human 51	
Active Ghrelin ELISA, EZGRA-88K, Millipore). Ghrelin-reactive IgG levels were measured using an 52	
adapted ELISA method [6]. To test specificity, and to determine if the autoantibodies also bind 53	
unacylated ghrelin (UAG), samples were pre-absorbed overnight with 10-6 M synthetic acylated 54	
ghrelin or UAG (Mimotopes, Australia) prior to the ELISA.  55	
 56	
Results 57	
PWS children were shorter in stature and displayed reduced lean mass compared to controls (Table 1). 58	
Mean fasting plasma acylated ghrelin levels were significantly higher in the PWS group (P < 0.01, 59	
Bonferonni-corrected two-way ANOVA; Figure 1A and Table 1), but postprandially ghrelin levels 60	
were similar to those in the control group after 60 minutes. Unlike acylated ghrelin, postprandial 61	
levels of ghrelin-reactive autoantibodies remained unchanged in both PWS and control children (P > 62	
0.05; Figure 1B). Children with PWS exhibited significantly higher fasting and postprandial levels of 63	
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plasma ghrelin-reactive autoantibodies than sibling controls (fasting comparison P < 0.0001, unpaired 64	
Student's t-test; Figure 1B). Pre-absorption of plasma with either acylated ghrelin or the non-65	
orexigenic isoform, UAG, decreased autoantibody levels in the PWS and control groups (P < 0.001, 66	
unpaired Student's t-test; Figure 1C, D).   67	
 68	
Discussion 69	
To our knowledge, this study represents the first evidence of an association between Prader-Willi 70	
Syndrome and ghrelin-reactive autoantibodies. Autoantibody levels were higher in children with PWS 71	
compared to sibling controls, both after fasting and for two hours postprandially. Critically, we 72	
demonstrate that, unlike plasma acylated ghrelin, ghrelin autoantibody levels remained constant 73	
regardless of food intake status.  74	
When considering the possible effects of ghrelin autoantibodies on the half-life of acylated 75	
ghrelin, the relative levels of both acylated ghrelin and ghrelin IgG should be considered. Acylated 76	
ghrelin levels decrease postprandially, while autoantibody levels remain constant. Therefore, the ratio 77	
of acylated ghrelin to ghrelin-reactive autoantibodies is reduced. In PWS, the constant elevation of 78	
ghrelin autoantibodies, which are believed to act as carrier proteins [5], could protect circulating 79	
ghrelin from degradation, potentiating its effect and contributing to hyperphagia, a key feature of this 80	
syndrome. Autoantibodies are thought to deliver acylated ghrelin to hypothalamic appetite-regulating 81	
centers, either directly or via the ghrelin receptor (GHSR) expressed by vagal afferents neurons. Pre-82	
incubation of plasma with supraphysiological levels of UAG reduced autoantibody levels detected in 83	
plasma ex vivo in both the PWS and control groups, indicating that autoantibodies bind multiple 84	
ghrelin isoforms and, that in excess, UAG may compete with acylated ghrelin for binding. Kinetic 85	
studies have yet to be performed, however, it is possible that PWS patients exhibit distinct ghrelin-86	
reactive antibody binding sites. Collectively, our data further implicate alterations of the ghrelin axis 87	
in PWS, and suggest that ghrelin autoantibodies can be targeted using non-orexigenic forms of 88	
ghrelin, thereby providing a novel therapeutic target for PWS and other ghrelin-associated disorders.  89	
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Figures and Tables: 128	
 129	
Figure 1: A) Plasma acylated ghrelin levels. B) Ghrelin-reactive autoantibodies are increased in PWS 130	
across the entire postprandial profile in the PWS group. C) Acylated ghrelin pre-absorption. D) 131	
Unacylated ghrelin (UAG) pre-absorption.  132	
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Table 1: Participant characteristics. Abbreviations: IgG, Immunoglobulin G; PWS, Prader-Willi 135	
Syndrome; f, female; m, male; BMI, body mass index. *Standard Deviation Score (Median; 136	
Interquartile range); cm, centimetres; aMean (± S.D.); #Mean (± S.E.M; pg/mL). Difference between 137	
PWS and control participants was determined using Student's t-test. 138	
                                Participant Characteristics  
 PWS Control P-value 
Gender 9f, 7m 6f, 10m  
Age (years)* 9.32 (5.29) 12.16 (6.12) 0.078 
Height* -0.39 (1.45) 1.03 (1.61) 0.049 
Weight* 1.05 (1.62) 1.26 (1.32) 0.545 
BMI* 1.50 (1.39) 1.10 (1.11) 0.423 
Waist:Height (cm) 0.55 (0.27) 0.50 (0.1) 0.055 
Lean mass (kg)a 26.00 (12.48) 44.84 (20.85) 0.013 
Acylated ghrelin 
(fasting)# 
764.2 (67.1) 517.2 (67.3) 0.021 
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